MENU
+Compare
EVAX
Stock ticker: NASDAQ
AS OF
Apr 2, 04:59 PM (EDT)
Price
$1.69
Change
+$0.03 (+1.81%)
Capitalization
10.49M

EVAX Evaxion Biotech A/S Forecast, Technical & Fundamental Analysis

Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs... Show more

EVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for EVAX with price predictions
Apr 01, 2025

EVAX in upward trend: price may ascend as a result of having broken its lower Bollinger Band on April 01, 2025

EVAX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 36 cases where EVAX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 54 cases where EVAX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EVAX advanced for three days, in of 174 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 25, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on EVAX as a result. In of 72 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EVAX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for EVAX entered a downward trend on April 01, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. EVAX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: EVAX's P/B Ratio (140.845) is slightly higher than the industry average of (13.458). P/E Ratio (0.000) is within average values for comparable stocks, (64.587). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.867). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (0.466) is also within normal values, averaging (251.391).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
EVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

EVAX is expected to report earnings to fall 19.05% to -17 cents per share on April 02

Evaxion Biotech A/S EVAX Stock Earnings Reports
Q4'23
Est.
$-0.17
Q3'23
Missed
by $0.02
Q2'23
Beat
by $0.01
Q1'23
Beat
by $0.02
Q4'22
Missed
by $0.03
The last earnings report on December 19 showed earnings per share of -20 cents, missing the estimate of -18 cents. With 24.22K shares outstanding, the current market capitalization sits at 10.49M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
Dr. Neergaards Vej 5f
Phone
+45 31319753
Employees
49
Web
https://www.evaxion-biotech.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LDOS134.960.02
+0.01%
Leidos Holdings
CCO1.10-0.01
-0.90%
Clear Channel Outdoor Holdings
GV3.17-0.09
-2.76%
Visionary Holdings Inc.
PSQH2.20-0.09
-3.93%
PSQ Holdings
SLNO68.26-3.19
-4.46%
Soleno Therapeutics

EVAX and Stocks

Correlation & Price change

A.I.dvisor tells us that EVAX and KURA have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EVAX and KURA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVAX
1D Price
Change %
EVAX100%
-10.27%
KURA - EVAX
31%
Poorly correlated
-3.33%
LPTX - EVAX
28%
Poorly correlated
-4.52%
CRGX - EVAX
28%
Poorly correlated
+1.23%
SPRB - EVAX
27%
Poorly correlated
-7.51%
REPL - EVAX
26%
Poorly correlated
-13.85%
More